BCL-X
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
26
06
2023
accepted:
17
01
2024
revised:
09
01
2024
medline:
2
3
2024
pubmed:
2
3
2024
entrez:
1
3
2024
Statut:
epublish
Résumé
Metastatic BRAF
Identifiants
pubmed: 38429301
doi: 10.1038/s41419-024-06478-z
pii: 10.1038/s41419-024-06478-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
183Subventions
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : 1046092
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : 1136119
Organisme : Victorian Cancer Agency (VCA)
ID : ECRF21035
Organisme : Victorian Cancer Agency (VCA)
ID : MCR19045
Informations de copyright
© 2024. The Author(s).
Références
Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011;50:307–12.
pubmed: 21305640
doi: 10.1002/gcc.20854
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.
pubmed: 12198537
doi: 10.1038/418934a
Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer. 2006;5:2.
pubmed: 16403224
doi: 10.1186/1476-4598-5-2
Seligmann JF, Fisher D, Smith CG, Richman SD, Elliott F, Brown S, et al. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol. 2017;28:562–8.
pubmed: 27993800
doi: 10.1093/annonc/mdw645
Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063–9.
pubmed: 16024606
doi: 10.1158/0008-5472.CAN-05-0404
Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013;14:749–59.
pubmed: 23725851
pmcid: 3699713
doi: 10.1016/S1470-2045(13)70163-3
Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol. 2011;29:2675–82.
pubmed: 21646616
doi: 10.1200/JCO.2010.34.5520
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707–14.
pubmed: 22356324
pmcid: 3724515
doi: 10.1056/NEJMoa1112302
Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Maru D, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol. 2015;33:4032–8.
pubmed: 26460303
pmcid: 4669589
doi: 10.1200/JCO.2015.63.2497
Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100–3.
pubmed: 22281684
doi: 10.1038/nature10868
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2:227–35.
pubmed: 22448344
pmcid: 3308191
doi: 10.1158/2159-8290.CD-11-0341
Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381:1632–43.
pubmed: 31566309
doi: 10.1056/NEJMoa1908075
Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON sStudy. J Clin Oncol. 2021;39:273–84.
pubmed: 33503393
pmcid: 8078423
doi: 10.1200/JCO.20.02088
Jenkins LJ, Luk IY, Fairlie WD, Lee EF, Palmieri M, Schoffer KL, et al. Genotype-tailored ERK/MAPK pathway and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell death. Mol Cancer Ther. 2023;22:52–62.
pubmed: 36343387
doi: 10.1158/1535-7163.MCT-22-0101
Rohrbeck L, Gong JN, Lee EF, Kueh AJ, Behren A, Tai L, et al. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM. Cell Death Differ. 2016;23:2054–62.
pubmed: 27689874
pmcid: 5136498
doi: 10.1038/cdd.2016.96
Shao Y, Aplin AE. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ. 2012;19:2029–39.
pubmed: 22858545
pmcid: 3504716
doi: 10.1038/cdd.2012.94
Sale MJ, Minihane E, Monks NR, Gilley R, Richards FM, Schifferli KP, et al. Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. Nat Commun. 2019;10:5167.
pubmed: 31727888
pmcid: 6856071
doi: 10.1038/s41467-019-12409-w
Gunda V, Sarosiek KA, Brauner E, Kim YS, Amin S, Zhou Z, et al. Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis. Cancer Lett. 2017;395:1–10.
pubmed: 28259821
doi: 10.1016/j.canlet.2017.02.028
Luo MJ, Palmieri M, Riffkin CD, Sakthianandeswaren A, Djajawi TM, Hirokawa Y, et al. Defining the susceptibility of colorectal cancers to BH3-mimetic compounds. Cell Death Dis. 2020;11:735.
pubmed: 32913182
pmcid: 7483443
doi: 10.1038/s41419-020-02815-0
Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2022;22:45–64.
pubmed: 34663943
doi: 10.1038/s41568-021-00407-4
Patterson CM, Balachander SB, Grant I, Pop-Damkov P, Kelly B, McCoull W, et al. Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021;4:112.
pubmed: 33495510
pmcid: 7835349
doi: 10.1038/s42003-020-01631-8
Carrel S, Sordat B, Merenda C. Establishment of a cell line (Co-115) from a human colon carcinoma transplanted into nude mice. Cancer Res. 1976;36:3978–84.
pubmed: 975046
Willson JK, Bittner GN, Oberley TD, Meisner LF, Weese JL. Cell culture of human colon adenomas and carcinomas. Cancer Res. 1987;47:2704–13.
pubmed: 3567899
Suardet L, Gaide AC, Calmes JM, Sordat B, Givel JC, Eliason JF, et al. Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2. Cancer Res. 1992;52:3705–12.
pubmed: 1617643
McBain JA, Weese JL, Meisner LF, Wolberg WH, Willson JK. Establishment and characterization of human colorectal cancer cell lines. Cancer Res. 1984;44:5813–21.
pubmed: 6498841
Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS, O’Connor L, Milla L, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015;10:1422–32.
pubmed: 25732831
doi: 10.1016/j.celrep.2015.02.002
Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA. Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer. Mol Cancer Ther. 2016;15:3015–27.
pubmed: 27765849
pmcid: 5136313
doi: 10.1158/1535-7163.MCT-16-0017
Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.
doi: 10.1038/nature11252
Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 2014;74:3238–47.
pubmed: 24755471
doi: 10.1158/0008-5472.CAN-14-0013
Wilson WH, O’Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149–59.
pubmed: 21094089
pmcid: 3025495
doi: 10.1016/S1470-2045(10)70261-8
Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173–86.
pubmed: 17382885
doi: 10.1016/j.cell.2007.01.037
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25:1938–47.
pubmed: 31792461
pmcid: 6898785
doi: 10.1038/s41591-019-0668-z
Balachander SB, Criscione SW, Byth KF, Cidado J, Adam A, Lewis P, et al. AZD4320, a dual inhibitor of Bcl-2 and Bcl-xL, induces tumor regression in hematologic cancer models without dose-limiting thrombocytopenia. Clin Cancer Res. 2020;26:6535–49.
pubmed: 32988967
doi: 10.1158/1078-0432.CCR-20-0863
Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10:138–48.
pubmed: 18204439
pmcid: 2376808
doi: 10.1038/ncb1676
Hubner A, Barrett T, Flavell RA, Davis RJ. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell. 2008;30:415–25.
pubmed: 18498746
pmcid: 2453504
doi: 10.1016/j.molcel.2008.03.025
Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem. 2003;278:18811–6.
pubmed: 12646560
doi: 10.1074/jbc.M301010200
Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003;22:6785–93.
pubmed: 14555991
doi: 10.1038/sj.onc.1206792
Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351–65.
pubmed: 16697956
doi: 10.1016/j.ccr.2006.03.027
Arulananda S, O’Brien M, Evangelista M, Jenkins LJ, Poh AR, Walkiewicz M, et al. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discov. 2021;7:122.
pubmed: 34050131
pmcid: 8163735
doi: 10.1038/s41420-021-00505-0
Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 2013;23:121–8.
pubmed: 23245996
doi: 10.1016/j.ccr.2012.11.007
Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology. 2009;50:1217–26.
pubmed: 19676108
doi: 10.1002/hep.23126
Weeden CE, Ah-Cann C, Holik AZ, Pasquet J, Garnier JM, Merino D, et al. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition. Oncogene. 2018;37:4475–88.
pubmed: 29743589
doi: 10.1038/s41388-018-0268-2